

1 TITLE PAGE

2

3 **Title:** Hydroxychloroquine/Chloroquine in COVID-19 With Focus on
4 Hospitalized Patients – A Systematic Review

5 **Authors/Affiliations:** Daniel Freilich (Bassett Medical Center), Jennifer Victory (Bassett
6 Research Institute), Anne Gadowski (Bassett Research Institute)

7 **Corresponding Author:** Daniel Freilich, MD

8 **CI Statement:** None of the authors have any Competing Interests to declare

9 **Authorship Role:** All authors collaborated in the writing/editing of the manuscript

10 **Article Type:** Review

11 **Keywords:** Hydroxychloroquine, chloroquine, COVID-19, SARS-CoV-2,
12 clinical trials, in vitro, animal studies

13 **Running Head:** Hydroxychloroquine/Chloroquine for COVID-19

14 **Key Summary Points:** Preclinical hydroxychloroquine/chloroquine *in vitro* studies found
15 inconsistent activity against coronaviruses including SARS-CoV-2.

16 Preclinical hydroxychloroquine/chloroquine animals studies found
17 inconsistent efficacy for coronaviruses in general and none for
18 SARS-CoV-2.

19 The overwhelming majority of RCTs and retrospective-
20 observational trials found no benefit for
21 hydroxychloroquine/chloroquine in hospitalized COVID-19
22 patients, and many found concerning safety signals.

23 The majority of RCTs and retrospective-observational trials found
24 no benefit for hydroxychloroquine/chloroquine in COVID-19
25 outpatients or for pre- or post-exposure prophylaxis, and some found
26 concerning safety signals.

27 The overwhelming majority of meta-analyses found no benefit for
28 hydroxychloroquine/chloroquine in COVID-19 inpatients,
29 outpatients, or for prophylaxis, and many found concerning safety
30 signals.

31

32

Abstract

Background

In the beginning of the COVID-19 pandemic, many hospitalized patients received empiric hydroxychloroquine/chloroquine (HC/CQ). Although some retrospective-observational trials suggested potential benefit, all subsequent randomized clinical trials (RCTs) failed to show benefit and use generally ceased. Herein, we summarize key studies that clinicians advising patients on HC/CQ's efficacy:safety calculus in hospitalized COVID-19 patients would want to know about in a practical one-stop-shopping source.

Methods

Pubmed and Google were searched on November 4, 2021. Search words included: COVID-19, hydroxychloroquine, chloroquine, *in vitro*, animal studies, clinical trials, and meta-analyses. Studies were assessed for import and included if considered impactful for benefit:risk assessment.

Results

These searches led to inclusion of 12 *in vitro* and animal reports; 12 retrospective-observational trials, 19 interventional clinical trials (17 RCTs, 1 single-arm, 1 controlled but unblinded), and 51 meta-analyses in hospitalized patients.

Inconsistent efficacy was seen *in vitro* and in animal studies for coronaviruses and nil in SARS-CoV-2 animal models specifically. Most retrospective-observational studies in hospitalized COVID-19 patients found no efficacy; QT prolongation and increased adverse events and mortality were reported in some. All RCTs and almost all meta-analyses provided robust data showing no benefit in overall populations and subgroups, yet concerning safety issues in many.

Conclusions

HC/CQ have inconsistent anti-coronavirus efficacy *in vitro* and in animal models, and no convincing efficacy yet substantial safety issues in the overwhelming majority of retrospective-

61 observational trials, RCTs, and meta-analyses in hospitalized COVID-19 patients. HC/CQ should
62 not be prescribed for hospitalized COVID-19 patients outside of clinical trials.

63

Introduction

More than 770,000 Americans have died of COVID-19, and U.S. deaths continue at 1,000-2,000 daily. Thus, it is imperative that we confirm the beneficial efficacy:safety calculus of effective medications (positive studies) but also the absence of beneficial efficacy:safety calculus of purportedly effective medications (negative studies), so we refrain from prescribing them potentially causing harm. Lessons should be learned from the successes and failures in response to the pandemic. The story of the medical community's empiric prescribing of hydroxychloroquine (HC) and chloroquine (CQ) despite weak *a priori* data and a progressively negative preclinical and clinical database during the pandemic should be instructive to avoid repetition in this latter phase of the pandemic.

HC received early pandemic attention for use in COVID-19 in part because then President Trump recommended and took it for post-exposure prophylaxis. HC was frequently administered empirically (peaking at a whopping 42% prevalence for hospitalized COVID-19 patients early in the pandemic [1]) and recommended in some expert reviews and guidelines (e.g., [2]). Supportive data were shaky, relying on inconsistent *in vitro* and animal studies mainly for other coronaviruses [3-4], and small flawed uncontrolled trials not confirming benefit [5-6]). Notwithstanding, the FDA issued an Emergency Use Authorization (EUA) in March 2020 for HC/CQ use in hospitalized COVID-19 patients who could not be enrolled in clinical trials [7].

Retrospective observational studies were subsequently published with the overwhelming majority finding no benefit and some finding higher mortality and toxicities (e.g., QTc prolongation) [6, 8-25], but they were fraught with potential bias, in part because HC/CQ patients were usually sicker. Most American guidelines recommended use in COVID-19 only in trials.

In late spring/early summer, 2020, results of at least 5 RCTs became available [26-30], with all showing no primary outcome benefit in hospitalized COVID-19 patients (and safety concerns in most). Most trialists studying treatments for hospitalized COVID-19 patients discontinued enrollment in their HC/CQ study arms by the summer of 2020. Twelve additional RCTs later in 2020, and in 2021, found similar results [31-42]. Numerous meta-analyses were completed assessing HC/CQ in hospitalized COVID-19 patients – almost all found ineffectiveness, and many found adverse safety signals (e.g., [43-45]).

This review summarizes the evolved benefits:risks database for HC/CQ in the COVID-19 pandemic, aiming to assist clinicians in easily summarizing the evidence basis for their benefits:risk assessment to their patients, some of whom (as well as other experts) continue to believe in possible effectiveness of these medications in some indications (e.g., [46]).

Methods

Pubmed and Google searches were conducted, with the latest repeated November 4, 2021. Initial search words included “COVID-19”, “hydroxychloroquine”, and “chloroquine”, found 3,123 publications.

Adding search words, “clinical trials”, reduced this list to 78 publications – 15 RCTs and 5 retrospective-observational trials in hospitalized patients, 4 RCTs in outpatients, 6 RCTs evaluating prophylaxis, and 48 other studies (not evaluating HC/CQ, not trials, unable to categorize). For hospitalized COVID-19 patients, the primary focus of this review, the Google search, as well as findings from the other Pubmed searches below (e.g., *in vitro* studies), led to inclusion of 4 additional studies (2 RCTs, 1 single-arm trial, and 1 prospective controlled observational trial) and 7 additional retrospective-observational trials yielding 19 interventional trials (17 of which were RCTs) and 12 retrospective-observational trials. Of the 17 RCTs, 5 published earlier in the pandemic were evaluated in detail systematically because they impacted evolving FDA recommendations and guidelines more than latter RCTs which tended to be confirmatory and additive to established literature (summarized but not detailed herein); all 5 included hard primary outcomes (i.e., mortality, ordinal scores, and viral clearance) with most comparing primary outcome risk, rate, and odds ratios; standard baseline patient characteristics were collected in all; 4 vs. 1 were assessed as having moderate and mild risk of bias, respectively (Table S1).

Adding “meta-analysis” to the Pubmed search led to 62 publications, 12 of whom were not focusing on hospitalized COVID-19 patients were excluded yielding a total of 50 meta-analyses; our unpublished IPD meta-analysis was added yielding a total of 51 meta-analyses in hospitalized patients (3 examples were detailed).

The Pubmed search led to the finding of 4 outpatient RCTs; the Google search found two additional studies (1 retrospective-observational study and 1 RCT) yielding a total of 6 outpatient studies.

The Pubmed search led to finding 6 prophylaxis studies; the Google search found an additional 3 studies (1 RCT, 2 observational cohort) yielding a total of 9 prophylaxis studies.

Adding the key words, “in vitro”, to our Pubmed search, resulted in 277 publications of which only 6 were in fact *in vitro* studies and thus included in our preclinical review. Our Google and other Pubmed searches found 2 additional studies, yielding 8 *in vitro* studies. Adding key words, “animal studies”, resulted in 89 publications of which only 4 were in fact animal studies and thus included in our preclinical summary; no additional studies were found with the Google or other Pubmed searches. In total, 12 preclinical studies were included in this review (8 *in vitro*, 4 animal).

See Figure 1.

We prioritized detailing of RCTs, larger retrospective-observational studies, and larger (especially IPD) meta-analyses as these were considered ‘more impactful’. Uncontrolled trials, smaller retrospective-observational studies, and smaller aggregate data meta-analyses (and as noted, later confirmatory RCTs) were considered ‘less impactful’.

This systematic review was not based on a written protocol nor was it registered.

Results and Discussion

Preclinical *In vitro* Studies

The anti-inflammatory and antimalarial medications, HC and CQ, demonstrated antiviral activity against SARS-CoV and MERS Co-V *in vitro*, including primate cells – although inconsistently as no activity was seen in SARS-CoV mouse cell culture [47].

A handful of reports showed SARS-CoV-2 growth inhibition *in vitro* by HC/CQ [48-50] including synergy with azithromycin at clinically realistic concentrations [51] – albeit similarly inconsistently as only two of three studies found viral growth inhibition in Vero E6 cell (African green monkey kidney cells) and one found no growth inhibition in a human airway epithelial model

[52-54]. One study found that growth inhibition by quinine exceeds that by HC or CQ in Vero cells, human Caco-2 colon epithelial cells, lung A549 cells, and Calu-3 lung epithelial cells [55].

The mechanism of action of HC/CQ's antiviral activity is purported to be via enhancement of endosomal pH leading to decreased viral-cell fusion and inhibition of glycosylation of SARS-CoV cellular receptors (both leading to decreased cell entry) [56]; immune modulation and anti-thrombotic characteristics may also be important. CQ EC50s of 0.77-6.9 microM have been reported, levels reached in patients receiving HC for rheumatoid arthritis [48, 12, 57]. One study reported an EC50 5.47 microM for CQ vs. 0.72 for HC for SARS-CoV-2 [58].

Overall, HC/CQ have *in vitro* activity against coronaviruses including SARS-CoV-2 albeit inconsistently and not as potently as some other antivirals [59].

Preclinical *In Vivo* Animal Studies

Animal studies evaluating HC/CQ for coronaviruses have been inconsistent. In mice, HC activity was found against the human coronavirus HCoV-OC43 [60] but none against SARS-CoV [47].

The limited database of animal studies with SARS-CoV-2 has been relatively 'negative.' Neither standard nor high dosing of prophylactic or therapeutic HC was efficacious in hamsters; standard prophylactic and therapeutic dosing was similarly ineffective in rhesus macaques [3]. Clinical parameters, viral shedding/load, and lung pathologic changes were similar in treatment and control groups. Another hamster study also showed no treatment or prophylaxis efficacy for HC [61]. In a ferret SARS-CoV-2 model, HC marginally decreased clinical scores at some time points but had no effect on symptoms duration or viral shedding or load [4]. In a macaque SARS-CoV-2 model, treatment dosing with HC with or without azithromycin had no effect on viral clearance, and prophylactic dosing did not decrease infection [54].

Notably, in other viral infections (e.g., influenza), CQ failed to replicate promising *in vitro* findings in *in vivo* animal and human studies [62].

The *in vitro* data for SARS viruses and relative safety of these medications in malaria and rheumatoid arthritis in part prompted recommendations by some expert groups and guidelines

early in the pandemic to administer these drugs empirically (ideally in RCTs) in COVID-19 [2, 63].

Retrospective-Observational Clinical Studies in Hospitalized Patients

Early in the pandemic, a small open-label non-randomized French trial was published, reporting results for HC treatment of hospitalized COVID-19 patients [8]. This pilot study received undue attention beyond its scientific and clinical significance, being referenced by then President Trump. Patients were given HC with or without azithromycin; patients from other hospitals and those refusing participation served as negative controls. The primary outcome measurement, day-6 virologic clearance by nasopharyngeal swab PCR, occurred in 70% of HC vs. 12.5% of control patients ($p=0.001$) (100% in HC/azithromycin patients and 57.1% in HC patients [$p<0.001$]); Six of 42 enrolled patients were lost to follow-up in the HC group. Mean serum HC concentration was $0.46 \text{ mcg/ml} \pm 0.2$, akin to EC50s published for CQ for SARS-CoV viruses. The trial was limited by small size, open-label design without true controls, short follow-up, and high dropout. The authors concluded their results were “*promising*” and recommended HC with azithromycin in COVID-19. In a follow-up reanalysis, the authors found that their results for HC/azithromycin were similar even after addressing critiques about excluded patients and outcome adjudication [8]. These results, however, could not be replicated in a subsequent study by other investigators [6].

Another small Chinese study early in the pandemic found improved clinical outcomes with HC in hospitalized COVID-19 patients [9]. The study randomized 62 patients to standard care with or without HC for 5 days in a double-blinded fashion. Time to Clinical Recovery, the primary outcome, was significantly shorter with HC. Improvement in pneumonia by CT imaging was higher with HC (80.6% vs. 54.8%).

In another early pandemic uncontrolled retrospective-observational study focused on hospitalized mechanically ventilated COVID-19 patients, also from China, mortality was 9/48 (18.8%) with HC vs. 238/502 (47.4%) without HC ($p<0.0001$) [10].

These small studies suggested that HC might have efficacy in COVID-19. Additional Chinese RCTs early in the pandemic led to the inclusion of recommendation in some Chinese guidelines to treat hospitalized COVID-19 patients with HC/CQ [11] after data from more than 100 patient

also showed less pulmonary complication and more rapid viral shedding and clinical improvement [12].

Based mainly on the limited preclinical data and these small early RCTs, in part, the FDA issued an EUA for HC/CQ for treatment of hospitalized COVID-19 patients for whom enrollment in trials was impractical on March 28, 2020 [7].

A small Brazilian trial was then published [13-14] demonstrating higher QTc prolongation rates (18.9% vs. 11.1%) and higher mortality (39% vs. 15% [OR, 3.6; 95% CI, 1.2-10.6]) with higher vs. lower CQ dosing for 81 hospitalized COVID-19 patients. There was no difference in viral shedding clearance. Prolonged QTc was not associated with death and no torsades de pointes occurred. Limitations included absence of placebo control and published mitigation strategies to reduce QTc prolongation (e.g., excluding baseline QTc prolongation and co-administration of additional QTc prolonging medications [100% received azithromycin]), single-center design, small sample size, and baseline imbalance.

Prolonged QTc was also reported in two additional retrospective case series of hospitalized COVID-19 patients treated with HC with or without azithromycin. In the small French series of 40 patients, baseline QTc > 460 msec was an exclusion. 93% developed some QTc prolongation; 36% developed more severe QTc prolongation (more commonly with concomitant azithromycin [33% vs. 5%, p=0.03]). No ventricular arrhythmias including torsades de pointes occurred. Seven patients (17.5%) stopped medication due to adverse events, ECG changes, or acute renal failure [15]. In the Boston series in 90 patients, combined therapy was associated with a larger median increase in the QT interval than HC monotherapy (23 vs. 5.5 msec, p=0.03), resulting in 13% vs. 3% of patients, respectively, having QTc change $\geq$ 60 msec. The risk of QTc prolongation to $\geq$ 500 msec was similar (21% vs. 19%). The authors implied a baseline QTc prolongation exclusion. Ten patients (11%) discontinued medication because of adverse events (nausea, hypoglycemia, and one case of delayed torsades de pointes) [16].

None of these series had control arms, so the relative risk of QTc prolongation remained elusive. Yet, it appeared that higher dosing and co-administration of QTc prolonging medications resulted in more frequent and severe QTc prolongation. Torsades de pointes, the feared QTc prolongation complication, appeared rare (occurring in only 1 of 211 patients in the series [0.5%]). An accompanying JAMA editorial concluded, the studies “underscore the potential risk ... of

hydroxychloroquine ... It is also true that ... the QTc can be safely monitored in most patients”
[64].

Based in part on these safety issues, the FDA issued a *Drug Safety Communication* on 24 April 2020 reminding providers about HC/CQ risks in COVID-19, mitigation strategies, and warning against use in outpatients and outside trials [65]. NIH COVID-19 guidelines in April 2020 concluded there remained equipoise for these drugs, and risk mitigation strategies should be employed if used. Some experts disagreed with the FDA’s allowance for continued empiric use despite emerging efficacy lapse yet concerning safety issues.

A retrospective study on 368 Wisconsin VA hospitalized COVID-19 patients compared mortality and mechanical ventilation with HC with or without azithromycin or neither. The study found higher mortality with HC vs. no HC (27.8% vs. 11.4%: adjusted HR, 2.61; 95% CI, 1.1-6.17, $p=0.03$) but no mechanical ventilation difference [17]. The study was small, retrospective/observational, and without randomization; HC patients were sicker.

Effects on mortality and intubation were equivocal in two large New York retrospective observational studies published in May 2020 [18-19]. The Columbia University study compared a composite outcome of intubation and death in 1,376 hospitalized COVID-19 patients treated with HC or not and found no significant associations in crude, multivariable, and propensity-score analyses [18]. The second study was in 1,438 hospitalized COVID-19 patients from 25 hospitals in NY State treated with HC with or without azithromycin or azithromycin alone [19]. In-hospital mortality was not statistically different, 25.7%, and 19.9% for HC with and without azithromycin, respectively, and 10% for azithromycin. More frequent cardiac arrest was found in patients receiving both drugs. No ECG abnormalities differences were found. HC patients were sicker in both studies.

After the NY studies, *Lancet* published the largest retrospective observational study to date, comparing in-hospital mortality and arrhythmias in 96,032 hospitalized COVID-19 patients treated with HC (or CQ) with or without azithromycin vs. neither [20]. In-hospital mortality and arrhythmias occurred significantly more frequently with HC/CQ, especially with azithromycin, in all analyses. Although larger, this study was limited by the same observational/retrospective

confounding as the prior studies. Although the authors reported similar between-group baseline characteristics, others found HC/CQ patients to be sicker. The publication was retracted. WHO temporarily halted HC arm enrollment in its *Solidarity* Trial after this publication.

Another French study in hospitalized COVID-19 patients (focusing on those requiring oxygen) compared mortality in 84 HC vs. 89 control patients. 21-day survival without ICU transfer was 76 vs. 75%, respectively (weighted hazard ratio 0.9, 95% CI 0.4 to 2.1). Eight HC patients (10%) developed arrhythmias of which 7 were QTc prolongation (vs. 0 in control patients) [21].

In May 2020, the FDA published *Pharmacovigilance Memorandum Safety* data from its *Adverse Event Reporting System (FAERS)* and other sources [66]. QT prolongation was the most common cardiac SAE, with co-administration of other QT-prolonging medications occurring in most cases; other cardiac SAEs included torsades de pointes in 4%, ventricular arrhythmia in 13%, and death in 23%. The most common non-cardiac SAE was increased LFTs. Four unexpected methemoglobinemia SAEs occurred.

A Weill Cornell Medicine (New York City) single-arm HC study in 153 patients found improvement in hypoxia scores in 52%, no ventricular arrhythmias, and QTc prolongation leading to drug discontinuation in 2% [23].

A Henry Ford Health System (southeast Michigan) study was reported^[22], comparing in-hospital mortality in 2,541 hospitalized COVID-19 patients treated with HC (13.5% [95% CI: 11.6-15.5%]), HC with azithromycin (20.1% [95% CI: 17.3%-23.0%], azithromycin 22.4% [95% CI: 16.0%-30.1%], and standard care 26.4% [95% CI: 22.2%-31.0%]. HC with or without azithromycin led to hazard ratio mortality reduction of 66-71%. Of all the larger retrospective trials, this study stands out as a positive one; however, it too was observational, without randomization or blinding, and confounded (e.g., steroids were given to 74.3-78.9% of HC vs. 35.7-38.8% of non-HC patients).

Two additional relatively small retrospective-observational studies reported decreased mortality with HC monotherapy and with co-administration with azithromycin [24-25]. In a single-site retrospective cohort study hospitalized patients with COVID-19 pneumonia, deaths occurred in 102/297 HC + azithromycin patients (34.3%) vs. 7/17 HC alone patients (41.2%) vs. 35/63 patients receiving neither due to ‘contraindications’ (55.6%). Use of HCQ + azithromycin (vs. no

treatment) was inversely associated with inpatient mortality HR 0.265 (95% CI 0.171-0.412, P<0.001) [24]. A preprint of an observational study from early in the pandemic in 255 hospitalized mechanically ventilated patients at a single New Jersey site reported a logistics regression survival odds ratio of 14.18 (95% CI, 4.05-55.61, p<0.0001) in patients receiving HC and azithromycin [25].

These studies were observational, without randomization or blinding, and with baseline imbalances and other potential sources of confounding.

RCTs in Hospitalized Patients

At last, results from at least five RCTs became available in the spring/summer of 2020 [26-30]. These are detailed below because they significantly impacted ensuing FDA and guidelines changes.

The first was a Chinese multicenter open-label RCT in 150 hospitalized laboratory-confirmed COVID-19 patients, 148 of whom had mild (negative chest x-ray) to moderate disease (positive chest x-ray) [26]. The mean interval from symptoms onset was 16.6 days. There was no significant difference in the main outcome measurement, intention-to-treat analysis of nasopharyngeal swab (SARS-CoV-2 PCR) negative conversion, which occurred in 85.4% of HC vs. 81.3% of standard care patients (difference 4.1%; 95% CI -10.3% to 18.5%). Adverse events (AEs) occurred in 30% vs. 9% (diarrhea most commonly), and SAEs occurred in 2 vs. 0 patients, respectively. No arrhythmias or QTc prolongation were reported. Study limitations included small size, delayed administration, early termination, open-label, other COVID-19 treatments, mild-moderate severity focus, and high dosing.

The second RCT was the *Recovery Trial* June 5, 2020, press release and eventual publication in *NEJM* on October 8, 2020 [27]. The pragmatic platform design included randomization but open-label, and standard care control without placebo – in 176 United Kingdom centers.⁽³⁶⁾ The mean interval from symptoms onset was 9 days. The trial included 17% of patients with severe disease (requiring mechanical ventilation or ECMO), 60% with moderate disease (requiring oxygen or noninvasive ventilation), and 24% with mild disease (requiring neither). The study's primary outcome measurement, 28-day mortality, was reached in 418/1,561 (26.8%) of HC vs. 788/3,155

(25%) of standard care patients (RR 1.09; 95% CI 0.96 to 1.23; $p=0.18$). Secondary outcomes included higher hospital length of stay (16 vs. 13 days, respectively), a higher composite endpoint of mechanical ventilation requirement and death (29.8% vs. 26.5%, respectively; RR 1.12; 95% CI 1.01-1.25), and higher stratified 28-day mortality trend in HC patients. Trial strengths included large size, randomization, control, and similar steroid use in both groups; limitations were open-label, absence of placebo, the inclusion of suspected (10%) and laboratory-confirmed (90%) cases (post-hoc analysis in confirmed cases yielded similar results), and absent multiple testing adjustment, block randomization, and pre-specification rules. Arrhythmias were not different (44.7% vs. 43%); one spontaneously resolved torsades des pointes SAE occurred with HC.

The FDA revoked its March 2020 EUA for HC/CQ for hospitalized patients with COVID-19 (outside trials) on June 15, 2020, based on results of the *Recovery Trial* and other emerging data [7].

An NIH press release on June 20, 2020, announced the final permanent cessation of enrollment in its *ORCHID* trial for futility after a fourth interim analysis showed no mortality benefit (albeit minimal safety issues). This (third) RCT provided the first robust, blinded, and placebo-controlled (not open-labeled) data for HC in hospitalized patients. Eventually published in JAMA on November 9, 2020, 479 patients were enrolled from 34 U.S. sites with a median interval from symptoms onset of 5 days (relatively early) [28]. Corticosteroids and azithromycin use was similar in the two treatment groups. The primary outcome measurement, the WHO 14-day ordinal score was similar in HC vs. placebo patients (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). No differences in secondary outcomes (including mechanical ventilation) – or mortality were found (10.4% vs. 10.6%, respectively) (absolute difference, -0.2% [95% CI, -5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]). QTc prolongation was more common with HC (5.9% vs 3.3%) but SAE rates were similar (5.8% vs. 4.6%).

A WHO press release on July 4, 2020, announced final permanent discontinuation of enrollment in its *Solidarity Trial* HC arm after interim analysis similarly showed no mortality benefit but concerning safety signals (fourth RCT).⁽³⁸⁾ Results were eventually published in NEJM on December 2, 2020 [29]. The primary outcome, intention-to-treat in-hospital mortality, in this large open-labeled RCT at 405 hospitals in 30 countries, occurred in 104 of 947 (11.0%) HC vs. 84 of 906 (9.3%) control patients (rate ratio, 1.19; 95% CI, 0.89-1.59, $p=0.23$); neither need for

mechanical ventilation nor hospital length of stay were significantly reduced by HC. The trial's open-label design without placebo is an obvious limitation but is unlikely to have biased mortality results.

The fifth spring/summer 2020 RCT, the *Coalition Covid-19 Brazil I* study [30] was multicenter, randomized, open-label, and controlled, comparing HC with or without azithromycin and standard care in 504 laboratory confirmed mild-moderate (requiring ≤ 4 L oxygen) hospitalized COVID-19 patients. The median interval from symptoms onset was 7 days. No differences were found for the primary outcome, clinical assessment at 15 days (seven-level ordinal score), comparing the treatment groups vs. the standard care group in a modified ITT analysis (confirmed cases only) (HC vs. standard care, OR 1.21; 95% CI, 0.69-2.11; $p=1.00$; HC with azithromycin vs. standard care, OR 0.99, 95% CI 0.57-1.73; $p=1.00$). QTc prolongation and LFTs elevation were more frequent with HC. Trial limitations consisted of open-design without placebo, smaller size, and restriction to mild-moderate severity.

Updated NIH and Infectious Diseases Society of America (IDSA) COVID-19 guidelines in June 2020 recommended HC/CQ use in hospitalized COVID-19 patients only in clinical trials; NIH (27 August 2020) and IDSA (20 August 2020) guidelines were then extended to an emphatic recommendation against HC/CQ use in hospitalized COVID-19 patients [67-68].

At least 12 additional RCTs were published evaluating HC/CQ in hospitalized COVID-19 patients published later on in the pandemic (winter of 2020, and in 2021). All showed similar absence of convincing evidence of benefit, and some worse primary outcome measurements (including clinical ordinal scales, mortality, composites, and viral shedding); some showed concerning safety signals including higher QTc prolongation, renal injury, and AE/SAE rates [31-42]. Outcomes from these RCTs are briefly summarized below.

A small RCT in 53 patients showed no difference in viral clearance between HC and HC/SOC treated patients [31]. An Egyptian RCT in 194 patients showed no difference in need for mechanical ventilation or mortality between HC and HC/SOC patient [32]. In New York University's TEACH double-blinded RCT in 128 patients comparing HC and placebo, there was no difference in the study's primary outcome, severe disease progression composite end point; viral clearance and AE rates were similar in the two treatment groups [33]. In Intermountain's

HAHPS RCT comparing 85 patients treated with HC vs. azithromycin with a Bayesian analysis, no convincing difference was found for the primary outcome, the 14-day ordinal score [34]; AE rates, QTc prolongation were similar but the AKI rate was numerically higher with HC. In a combined report of a Taiwanese small open-labeled RCT (n=34) and small retrospective study (n=37), 14-day viral clearance was similar with or without HC [35]. In a Brazilian open-labeled RCT in 105 patients, addition of HC or CQ to SOC resulted in significant worsening of the primary outcome, a 14-day 9-point clinical ordinal score, as well as need for mechanical ventilation and severe AKI (but not arrhythmias) [36]. In another Brazilian RCT in 168 patients randomized to receive HC, CQ, or ivermectin, there were no significant differences in the primary endpoints, need for oxygen or mechanical ventilation, ICU admission, or mortality [37]. In the REMAP-CAP trial in patients were treated with lopinavir-ritonavir (n=255), HC (n=50), combination therapy (n=27) or control (n=362), a Bayesian analysis of its primary endpoint of an ordinal scale of organ support-free days (as well as mortality) showed significantly worse outcome with all 3 treatments vs. control [38]. In HYCOVID, a double-blinded RCT in 247 patients with milder disease in France and Monaco comparing HC and placebo, neither the primary outcome of a 14-day composite of death and need for mechanical ventilation, nor viral clearance, were different [39]. In a Mexican double-blinded RCT in 214 patients comparing HC and placebo, neither the primary outcome, 30-day mortality, nor any secondary outcomes differed [40]. In NOR-Solidarity, a Norwegian add-on study to WHO's *SOLIDARITY* trial, viral clearance, respiratory failure severity, and inflammatory variables were compared (and in-hospital mortality) in 185 patients receiving remdesivir, HC, or SOC. There were no group differences for any of these variables [41]. In a Danish double-blinded, placebo-controlled RCT in 117 patients, the primary outcome, days alive and discharged from hospital by 14 days, did not differ between HC/azithromycin vs. placebo/placebo [42]. See Table 1.

A prospective controlled but unrandomized trial in 66 patients in Brazil also failed to show a difference in viral clearance [69].

An interesting and telling study from Israel found, for therapeutics in COVID-19, low concordance between published observational studies (often 'positive') and RCTs (usually 'negative'), akin to findings in this HC/CQ review [70].

Key limitations of these 17 RCTs include moderate risk of bias in 13 (majority) and optimal double-blinded placebo-controlled design in only 5 (minority).

Meta-analyses in Hospitalized Patients

In the overwhelming majority of 50 published aggregate data meta-analyses (AD-MAs) and in our IPD-MA [45] assessing HC/CQ in hospitalized COVID-19 patients, no convincing efficacy was found, and in many adverse safety signals were noted. Ten of these reported limited patient level subgroup analyses with a pattern of subgroup results paralleling overall results. Three AD-MA examples follow:

A large *Open Society Foundation* AD-MA from 14 published and 14 unpublished HC (26 trials) and CQ (4 trials) studies was published; 67% of the sample size of 10,319 patients was derived from the *RECOVERY* and *SOLIDARITY* trials [43]. Mortality was found to be higher with HC (OR 1.11 [95% CI: 1.02-1.20; 26 trials; 10,012 patients]) and equivocal for CQ (OR 1.77 [95% CI: 0.15-21.13, 4 trials; 307 patients]). Patient level subgroup analysis was restricted to disease severity.

A Cochrane AD-MA from 12 RCTs with 8,569 COVID-19 patients [44]. No differences were found for HC/CQ vs. control treatment for mortality (RR 1.09, 95% CI 0.99-1.19), mechanical ventilation (RR 1.11, 95% CI 0.91-1.37), or conversion to negative nasopharyngeal swabs (RR 1.00, 95% CI 0.91-1.10); AEs were more frequent with treatment (RR 2.90, 95% CI 1.49-5.6) but not SAEs (RR 0.82, 95% CI 0.37-1.79). Subgroup analyses were planned but not completed due to inability to secure necessary data.

Results of an IPD-MA of 8 U.S. RCTs evaluating HC/CQ in hospitalized COVID-19 patients also showing no credible efficacy in hospitalized COVID-19 patients in the overall population (OR 0.95; 95% credible interval 0.77 to 1.22) and in a comprehensive analysis of multiple patient level subgroups (NCOSS (a disease severity surrogate), age, gender, number of comorbidities, BMI, and estimated baseline risk) was recently submitted for publication [45]. Overall AE, SAE, and elevated LFTs AE rates were numerically higher with HC/CQ but not QTc prolongation or arrhythmias.

Clinical Studies in Other Indications

Outpatients

A retrospective-observational trial from New Jersey comparing outcome in 1274 HC treated outpatients with COVID-19 and 1067 patient propensity-matched cohort, hospitalization occurred in 21.6% vs. 31.4%, respectively (OR 0.53; 95% CI, 0.29-0.95) [71].

Akin to results in inpatients (above), RCTs failed to show HC/CQ efficacy in outpatients:

A double-blinded and placebo-controlled RCT was published evaluating HC in 423 COVID-19 outpatients (81% laboratory-confirmed or exposed to a laboratory-confirmed individual) with mild disease [72]. Change in a symptom severity score over 14 days, the study's primary outcome measurement, was not statistically different, nor were hospitalization rates. Mild adverse events were more common with HC.

Another RCT in COVID-19 outpatients, Q-PROTECT, randomized patients with mild-moderate symptoms to placebo or HC with or without azithromycin. In the 456 patients enrolled, viral cure (PCR negativity at day 6), the primary outcome measurement, was similar in all three groups (12.2%, 10.5%, and 12.8%, respectively; $p=0.821$) [73].

In another RCT in COVID-19 outpatients (all were laboratory-confirmed) in Alberta, HC and placebo were compared. Treatment occurred at a mean of 12 days after symptoms onset. The primary outcome, a composite of 30-day hospitalization/mechanical ventilation/death occurred in 4 of 111 randomized HC patients (4 hospitalizations) vs. 0 of 37 placebo patients. Symptoms duration was not decreased either. The study was terminated prematurely due to slow recruitment [74].

A RCT from Brazil compared outcome in 685 COVID-19 outpatients randomized to receive HC, lopinavir/ritonavir, or placebo. The primary outcome, hospitalizations, occurred in 3.7% vs. 5.7% vs. 4.8%, respectively (HR 0.76, 95% CI, 0.30-1.88). There were no secondary outcomes group differences either (mortality, viral shedding) [75].

A small placebo-controlled RCT in 84 outpatients found no difference in 9-day viral clearance between HC and placebo [76].

In summary, HC/CQ has not been found to have significant efficacy in outpatients with COVID-19 yet increased AEs in some studies, however the published database is more limited than for hospitalized patients.

Post exposure prophylaxis

A post-exposure prophylaxis study was reported in which 821 subjects with moderate- or high-risk household or occupation exposure were randomized to receive HC or placebo within 4 days of exposure [77-78]. The primary outcome, “*incidence of new illness compatible with Covid-19*” (fewer than 3% were laboratory confirmed) was not different (11.8% vs. 14.3%, $p=0.35$). None-serious AEs were more common with HC.

Another post-exposure prophylaxis study in 2,314 with an open-label cluster-randomization design found the primary outcome of PCR-confirmed symptomatic COVID-19 infection to be similar in HC vs. usual care patients (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]); non-serious adverse events were much more common with HC (56.1% vs. 5.9%) but no ‘related’ SAEs occurred [79].

In another post-exposure prophylaxis study, household exposures within 96 hours were randomized to receive HC ($n=407$) or vitamin C placebo ($n=334$). Among 689 participants who were PCR swab at baseline, conversion to positive PCR (the primary outcome) occurred 53 vs. 45 subjects (adjusted HR, 1.10, 95% CI, 0.73-1.66; $p>0.2$). The AE rate was significantly higher with HC (16.2 vs. 10.9%, $p=0.026$) [80].

In summary, HC/CQ has not been found to have significant efficacy for pre-exposure prophylaxis against COVID-19 yet increased AEs, however the published database is more limited than for hospitalized patients.

Pre-exposure prophylaxis

Four pre-exposure prophylaxis studies (two double-blind placebo-controlled RCTs in healthcare workers and two large observational retrospective population-based studies in rheumatoid arthritis and lupus patients) showed no differences in COVID-19 infection rates [81-83] or mortality [84].

A descriptive safety analysis from three of these outpatient RCTs (1 non-hospitalized mild-moderate disease RCT, 1 post-exposure prophylaxis RCT, and 1 pre-exposure prophylaxis RCT) in 2,795 subjects found increased AE rates with HC (36-40%) vs. placebo (19%) but rare SAEs; GI upset was the most common AE. Co-administration of other QT prolonging medications was an exclusion in these RCTs [85].

An open-label cluster study in migrants in Singapore showed higher viral clearance with HC vs. vitamin C control [86]. An Indian open-labeled, controlled study in 317 exposed or presumed exposed subjects showed significantly decreased infection rates with HC post-exposure prophylaxis vs. SOC [87].

A potential critique of some of the post-exposure prophylaxis studies has been that HC/CQ was sometimes administered late after symptoms onset leading to decreased efficacy – as occurs with delayed neuraminidase inhibitor treatment for influenza and in some experimental SARS-CoV-2 mouse models [88]. Higher dosing than necessary based on predicted pharmacokinetics, leading to more adverse events, has also been a critique.

An unpublished medRxiv aggregate data meta-analysis including five pre- and post-exposure prophylaxis RCTs reported possible benefit for HC [89].

In summary, HC/CQ has not been found to have significant efficacy for pre-exposure prophylaxis against COVID-19 in most but not all studies and increased AEs in some, however the published database is much more limited than for hospitalized patients.

Study limitations

The key limitation of this review is that systematic adherence to PRISMA checklist [90] components was high for HC/CQ studies in hospitalized patients (the focus of this review) but lower for the other studies (e.g., no risk of bias assessment in the latter).

Conclusions

This systematic review of preclinical *in vitro* and animal studies, retrospective-observational trials, RCTs, and meta-analyses strongly suggests that HC/CQ are ineffective in hospitalized patients

with COVID-19, both in overall populations and in subpopulations, and should not be administered outside of RCTs with robust informed consent about unlikely benefit and probable harm. We believe that the preclinical and clinical database was never sufficient to support empiric use.

The published clinical trials database for HC/CQ in outpatients and post-exposure and pre-exposure prophylaxis also shows lack of convincing efficacy despite increased adverse events, but it is more limited than for hospitalized patients, particularly for pre-exposure prophylaxis. Our review was less robust for these indications.

Empiricism, particularly when based mainly on retrospective-observational studies rather than RCTs, is fraught with danger for patients. Cognizance of the story of HC/CQ's failure during the COVID-19 pandemic should lead to refraining on the part of the medical community from repeating the same errors for other experimental therapeutics. Dr. Kalil's wise admonition in his May 2020 *JAMA* viewpoint bears repeating: "*The administration of any unproven drug as a 'last resort' wrongly assumes that benefit will be more likely than harm*" [91].

Acknowledgments

We thank Dr. Kunjal Luhadia, MD, for her helpful manuscript edits.

Funding Source

None.

References

1. Mehta HB, An H, Andersen KM et al. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States. A Retrospective Cohort Study. *Ann Int Med*. 2021;174(10):1395-1403.
2. Wilson K, Chotirmall SH, Bai C, Rello J. Interim Guidance on Management Pending Empirical Evidence. From an American Thoracic Society-led International Task Force: From an American Thoracic Society-led International Task Force; 2020 [Available from: <https://www.thoracic.org/covid/covid-19-guidance.pdf>].
3. Rosenke K, Jarvis MA, Feldmann F, et al. Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. *JCI Insight*. 2020;5(23):e143174.
4. Park SJ, Yu KM, Kim YI, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. *mBio*. 2020;11(3):e01114-20.
5. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19 results of an open-label non-randomized clinical. *Int J Antimicrob Agents*. 2020;56(1):105949.
6. Molina JM, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Med Mal Infect*. 2020;50(4):384.
7. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease. March 28, 2021. Revoked, June 15, 2021. <https://www.fda.gov/media/136534/download>.
8. Gautret, P, Hoang VT, Lagier, J-C, Raoult D. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. *Int J Antimicrob Agents*. 2021;57(1):106239.
9. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv*. 2020:2020.03.22.20040758.
10. Yu B, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. *Sci China Life Sci*. 2020;63(10):1515-1521.
11. Qiu T, Liang S, Dabbous M, Wang Y, Han R, Toumi M. Chinese Guidelines Related to Novel Coronavirus Pneumonia. *J Mark Access Health Policy*. 2020;8(1):1818446.
12. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020;14(1):72-3.
13. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. *JAMA Network Open*. 2020;3(4):e208857.
14. Fihn SD, Perencevich E, Bradley SM. Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019. *JAMA Network Open*. 2020;3(4):e209035.
15. Bessière F, Rocchia H, Delinière A, Charrière R, Chevalier P, Argaud L, et al. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19)

- Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiology*. 2020;5(9):1067-1069.
16. Mercurio NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology*. 2020;5(9):1036-1041.
17. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. *Med*. 2020;1(1):114-127.e3.
18. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*. 2020;382(25):2411-8.
19. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. *JAMA*. 2020;323(24):2493.
20. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *The Lancet*. 2020;S0140-6736(20)31180-6.
21. Mahevas M, Tran V, Roumier M, et al. Clinical Efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *BMJ* 2020;369:m1844.
22. Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. *International Journal of Infectious Diseases*. 2020;97:396-403.
23. Satlin MJ, Goyal P, Magleby R, et al. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. *PLoS One*. 2020;15(7):e0236778.
24. Lauriola M, Pani A, Ippoliti G, et al. Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. *Clin Transl Sci*. 2020;13(6):1071-76.
25. Smith LG, et al. Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic. *Medrxiv preprint*. <https://www.medrxiv.org/content/10.1101/2021.05.28.21258012v1.full.pdf>.
26. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020;369:m1849.
27. Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. The RECOVERY Collaborative Group. *N Engl J Med*. 2020;383:2030-40.
28. Self W, Semler MW, Lindsay LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19A Randomized Clinical Trial. *JAMA*. 2020;324(21):2165-76.
29. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. WHO Solidarity Trial Consortium. *N Engl J Med*. 2021;384:497-511.
30. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020;383:2041-52.

31. Lyngbakken MN, Berdal JE, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. *Nature Communications*. 2020;11(1):5284.
32. Abd-Elsalam S, Esmail ES, Khalaf M, et al. Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study. *Am J Trop Med and Hyg*. 2020;103(4):1635-39.
33. Ulrich RJ, Troxel AB, Carmody E, et al. Treating COVID-19 with hydroxychloroquine (TEACH): a multicenter, double-blind randomized controlled trial in hospitalized patients. *Open Forum Infectious Diseases*. 2020;7(10):ofaa446.
34. Brown SM, Peltan I, Kumar N, et al. Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. *Ann Am Thorac Soc*. 2020;9;18(4):590-7.
35. Chen CP, Lin YC, Chen TC, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). *PloS One*. 2020;15(12):e0242763.
36. Réa-Neto Á, Bernardelli RS, Câmara BMD, Reese FB, Queiroga MVO, Oliveira MC. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. *Scientific Reports*. 2021;11(1):9023.
37. Galan LEB, Santos NM dos, Asato MS, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. *Pathogens and Global Health*. 2021;115(4):235-42.
38. Arabi YM, Gordon AC, Derde LPG, et al. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. *Intensive Care Med*. 2021;47(8):867-86.
39. Dubée V, Roy PM, Vielle B, et al. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. *Clin Microbiol Infect*. 2021;27(8):1124-30.
40. Hernandez-Cardenas C, Thirion-Romero I, Rodríguez-Llamazares S, et al. Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: a randomized controlled trial. *PloS One*. 2021;16(9):e0257238.
41. Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial. *Ann Intern Med*. 2021;174(9):1261-69.
42. Sivapalan P, Ulrik CS, Lapperre TS, et al. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. *Eur Respir J*. 2021:2100752.
43. Axfors C, Schmitt AM, Janiaud P, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. *Nat Commun*. 2021;12(1):2349.
44. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. *Cochrane Database Syst Rev*. 2021;2(2):CD013587.
45. Di Stefano L, et al. Hydroxychloroquine or Chloroquine for the Treatment of Hospitalized Patients with COVID-19. An Individual Participant Data Meta-Analysis. Manuscript submitted.

46. Hernan M. Causal inference in a time of coronavirus: tenofovir, tocilizumab, hydroxychloroquine. Harvard T.H. Chan School of Public Health. <https://www.lshtm.ac.uk/newsevents/events/causal-inference-time-coronavirus-tenofovir-tocilizumab-hydroxychloroquine> and <https://www.lshtm.ac.uk/media/44276>.
47. Barnard DL, Day CW, Bailey K, et al. Evaluation of Immunomodulators, Interferons and Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice. *Antiviral Chemistry and Chemotherapy*. 2006;17(5):275-84.
48. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020;30(3):269-71.
49. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*. 2020;6(1).
50. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology*. 2005;2:69.
51. Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog*. 2020;145:104228.
52. Kang CK, Seong MW, Choi SJ, et al. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses. *Korean J Intern Med*. 2020;35(4):782-87.
53. Gendrot M, Andreani J, Boxberger M, et al. Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. *Travel Med Infect Dis*. 2020;37:101873.
54. Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. *Nature*. 2020;585(7826):584-87.
55. Große M, Ruetalo N, Layer M, et al. Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. *Viruses*. 2021;13(4):647.
56. Morrisette T, Lodise TP, Scheetz MH, Goswami S, Pogue JM, Rybak MJ. The pharmacokinetic and pharmacodynamic properties of hydroxychloroquine and dose selection for COVID-19: putting the cart before the horse. *Infect Dis Ther* 2020;9:561-72.
57. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. *Int J Antimicrob Agents*. 2020;55(4):105932.
58. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis*. 2020;71(15):732-39.
59. White NJ, Watson JA, Hoglund RM, Chan XHS, Cheah PY, Tarning J. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. *PLOS Medicine*. 2020;17(9):e1003252.
60. Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. *Antimicrob Agents Chemother*. 2009;53(8):3416-21.
61. Kaptein SJF, Jacobs S, Langendries L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. *Proc Natl Acad Sci USA*. 2020;117(43):26955-65.
62. Vigerust DJ, McCullers JA. Chloroquine is effective against influenza A virus in vitro but not in vivo. *Influenza and Other Respiratory Viruses*. 2007;1(5-6):189-92.
63. Zhonghua J, He H, Hu X, Za Z. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. *Zhonghua Jie He He Hu Xi Za Zhi*. 2020;43(3):185-8.
64. Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. *JAMA Cardiol*. 2020;5(9):986-87.

65. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. <https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or>.
66. Food and Drug Administration. Pharmacovigilance Memorandum. Hydroxychloroquine and chloroquine [updated May 19, 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/0SE%20Review_Hydroxychloroquine-Chloroquine%20-%2019May2020_Redacted.pdf.
67. National Institute of Health. Chloroquine or Hydroxychloroquine With or Without Azithromycin 2020 [updated August 27, 2020; cited 2020 September 19, 2020]. Available from: <https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/chloroquine-or-hydroxychloroquine/>.
68. Infectious Diseases Society of America. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 2020 [September 19, 2020]. Available from: <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>.
69. Faíco-Filho KS, Conte DD, de Souza Luna LK, Carvalho JMA, Perosa AHS, Bellei N. No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19. *Braz J Microbiol.* 2020;51(4):1765-69.
70. Shepshelovich D, Yahav D, Ben Ami R, Goldvaser H, Tau N. Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. *J Antimicrob Chemother.* 2021;76(9):2415-18.
71. Ip A, Ahn J, Zhou Y, et al. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. *BMC Infect Dis.* 2021;72(2021).
72. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. *Ann Intern Med.* 2020;173(8):623-31.
73. Omrani AS, Pathan SA, Thomase SA, et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. *EClinicalMedicine.* 2020;29:100645.
74. Schwartz I, Boesen ME, Cerchiaro G, et al. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial. *CMAJ Open.* 2021 Jun 18;9(2):E693-E702.
75. Reis G, dos Santos Moreira Silva EA, Silva DCM, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. The TOGETHER Randomized Clinical Trial. *JAMA Netw Open.* 2021;4(4):e216468.
76. Rodrigues C, et al. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. *Int J Antimicrob Agents.* 2021;58(5):106428.
77. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med.* 2020;383(6):517-25.
78. Cohen MS. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. *N Engl J Med.* 2020;383(6):585-6.
79. Mitja O, Corbacho-Monné, Ubals M, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. *N Engl J Med.* 384(5):417-27.

80. Barnabas RV, Brown ER, Bershteyn A, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial. *Ann Intern Med.* 2021;174(3):344-52.
81. Abella BS, Jolkovsky EL, BA; Biney BT, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. *JAMA Intern Med.* 2021;181(2):195-202.
82. Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial. *Clin Infect Dis.* 2021;72(11):e835-e843.
83. Jung S-Y, Kim M-S, Kim M-C et al. Effect of Hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. *Clin Microbiol Infect.* 2021;27(4):611-617.
84. Rentsch CT, DeVito NJ, MacKenna B, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. *Lancet Rheumatol.* 2021;3(1) E19-E27.
85. Lofgren SM, Nicol MR, Bangdiwala AS, et al. Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. *Open Forum Infect Dis* 2020;7(11): ofaa500.
86. Seet RCS, Quek AML, Ooi DSQ, et al. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial. *Int J Infect Dis.* 2021;106:314-22.
87. Dhibar DP, Arora N, Kakkar A, et al. Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. *Int J Antimicrob Agents.* 2020;56(6):106224.
88. Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci Transl Med.* 2020;12(541):eabb5883.
89. García-Albéniz X, del Amo J, Polo R, et al. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19. <https://www.medrxiv.org/content/10.1101/2020.09.29.20203869v4>.
90. Kalil AC. Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. *JAMA.* 2020;323(19):1897-98.
91. PRISMA. Transparent Reporting of Systematic Reviews and meta-analyses. <http://prisma-statement.org/PRISMAStatement/Checklist>.
92. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. *BMJ.* 2011;343:d5928.

816 **Table 1. RCTs evaluating HC/CQ in hospitalized patients with COVID-19**

Reference	N	Design	Comparators	Primary outcome	Primary results	Other results
Tang W [26]	150	Open-label	HC+SOC vs. SOC	Viral clearance	No significant difference	Numerically more AEs with HC but no arrhythmias or QTc prolongation.
Horby PW [27] <i>RECOVERY</i>	4,716	Open-label, platform	HC+SOC vs. SOC	28-day mortality	No significant difference	Higher composite endpoint of mechanical ventilation requirement & death with HC. Arrhythmias were similar.
Self W [28] <i>ORCHID</i>	479	Double-blinded, placebo-controlled	HC+SOC vs. Placebo+SOC	WHO 14-day ordinal score	No significant difference	Mortality and mechanical ventilation need were similar. QTc prolongation was numerically higher with HC but SAEs were similar.
Pan H [29] <i>SOLIDARITY</i>	1,853	Open-label, platform	HC+SOC vs. SOC	In-hospital mortality	No significant difference	Mechanical ventilation need & LOS were similar.
Cavalcanti AB [30] <i>Coalition Covid-19 Brazil I</i>	504	Open-label, mild-moderate severity	HC+SOC vs. SOC & HC+AZ+SOC vs. SOC	15-day ordinal score	No significant differences	QTc prolongation & elevated LFTs were numerically higher with HC.
Lyngbakken MN [31]	53	Open-label	HC+SOC vs. SOC	Viral clearance	No significant difference	Mortality, ordinal score, & LOS were similar.
Abd-Elsalam S [32]	194	Open-label	HC+SOC vs. SOC	Need for mechanical ventilation or death	No significant differences	
Ulrich RJ [33] <i>TEACH</i>	128	Double-blinded, placebo-controlled	HC+SOC vs. Placebo+SOC	Composite of severe disease progression	No significant difference	Viral clearance & AEs were similar.
Brown SM [34] <i>HAHPS</i>	85	Open-label, AZ control, Bayesian analysis	HC vs. AZ	14-day ordinal score	No significant difference	AEs & QTc prolongation were similar but AKIs were numerically higher with HC.
Chen CP [35]	34	Open-label	HC+SOC vs. SOC	Viral clearance	No significant difference	
Rea-Neto A [36]	105	Open-label	HC/CQ+SOC vs. SOC	14-day ordinal score	Significantly worse with HC	Mechanical ventilation need and severe AKIs were significantly higher with HC. Arrhythmias were similar.
Galan LEB [37]	168	Double-blinded, ivermectin-controlled	HC vs. CQ. vs. ivermectin	Need for O2 or mechanical ventilation, ICU admission, or mortality	No significant differences	SAEs were similar.
Arabi YM [38] <i>REMAP-CAP</i>	694 L-R(N=255) HC (N=50) L-R & HC (N=27) SOC (N=362)	Open-label, platform, Bayesian analysis	Lopinavir-ritonavir+SOC vs. HC+SOC vs. lopinavir-ritonavir & HC+SOC vs. SOC	Ordinal scale of organ support-free days	Significantly worse with all 3 treatments	Significantly worse mortality with all 3 treatments.
Dubee V [39] <i>HYCOVID</i>	247	Double-blinded, placebo-controlled	HC+SOC vs. Placebo+SOC	14-day composite of death & need for mechanical ventilation	No significant difference	Viral clearance, ordinal scores, & AEs & SAEs were similar.
Hernandez-Cardenas C [40]	214	Double-blinded, placebo-controlled	HC+SOC vs. Placebo+SOC	30- day mortality	No significant difference	Need for mechanical ventilation, LOS, & SAEs were similar.
Barratt-Due A [41] <i>NOR-Solidarity</i>	185	Open-label, platform, add-on to <i>SOLIDARITY</i>	HC+SOC vs. remdesivir+SOC vs. SOC	Viral clearance	No significant difference	Respiratory failure severity, inflammatory variables, & in-hospital mortality were similar.
Sivapalan P [42]	117	Double-blinded, placebo-controlled	HC/AZ+SOC vs. Placebo/Placebo+SOC	Days alive & discharged from hospital by 14 days	No significant difference	Diarrhea was numerically higher with HC/AZ but QTc prolongation and SAEs were numerically higher with Placebo.

817 **Figure legends**

818

819 **Figure 1**

820 Pubmed and Google searches were used to query the published preclinical and clinical literature
821 for hydroxychloroquine and chloroquine use for treatment and prophylaxis in COVID-19

